

PART VI: SUMMARY OF THE RISK MANAGEMENT PLAN

Summary of Risk Management Plan for Pazopanib Viatriis 200 mg and 400 mg film-coated tablets (pazopanib)

This is a summary of the risk management plan (RMP) for Pazopanib Viatriis 200 mg and 400 mg film-coated tablets. The RMP details important risks of pazopanib, how these risks can be minimised, and how more information will be obtained about pazopanib's risks and uncertainties (missing information).

Pazopanib Viatriis 200 mg and 400 mg film-coated tablets's summary of product characteristics (SmPC) and its package leaflet give essential information to healthcare professionals and patients on how it should be used.

Important new concerns or changes to the current ones will be included in updates of Pazopanib Viatriis 200 mg and 400 mg film-coated tablets's RMP.

I. The Medicine and What it is Used For

Pazopanib Viatriis 200 mg and 400 mg film-coated tablets is authorised in adults for the first-line treatment of advanced renal cell carcinoma (RCC) and for patients who have received prior cytokine therapy for advanced disease. Pazopanib Viatriis 200 mg and 400 mg film-coated tablets is indicated for the treatment of adult patients with selective subtypes of advanced soft-tissue sarcoma (STS) who have received prior chemotherapy for metastatic disease or who have progressed within 12 months after (neo) adjuvant therapy. It contains pazopanib as the active substance and it is given by oral route of administration.

II. Risks Associated with the Medicine and Activities to Minimise or Further Characterise the Risks

Important risks of Pazopanib Viatriis 200 mg and 400 mg film-coated tablets, together with measures to minimise such risks are outlined below.

Measures to minimise the risks identified for medicinal products can be:

- Specific Information, such as warnings, precautions, and advice on correct use, in the package leaflet and SmPC addressed to patients and healthcare professionals;
- Important advice on the medicine's packaging;
- The authorised pack size — the amount of medicine in a pack is chosen so to ensure that the medicine is used correctly;
- The medicine's legal status — the way a medicine is supplied to the public (e.g. with or without prescription) can help to minimise its risks.

Together, these measures constitute routine risk minimisation measures.

In addition to these measures, information about adverse events is collected continuously and regularly analysed, so that immediate action can be taken as necessary. These measures constitute routine pharmacovigilance activities.

EU Risk Management Plan Pazopanib Version 0.2

II.A List of Important Risks and Missing Information

Important risks of Pazopanib Viatriis 200 mg and 400 mg film-coated tablets are risks that need special risk management activities to further investigate or minimise the risk, so that the medicinal product can be safely taken by patients. Important risks can be regarded as identified or potential. Identified risks are concerns for which there is sufficient proof of a link with the use of Pazopanib Viatriis 200 mg and 400 mg film-coated tablets. Potential risks are concerns for which an association with the use of this medicine is possible based on available data, but this association has not been established yet and needs further evaluation. Missing information refers to information on the safety of the medicinal product that is currently missing and needs to be collected (e.g. on the long-term use of the medicine/use in special patient populations etc.).

Table 3: Part VI.1- Summary of safety concerns

List of Important Risks and Missing Information	
Important Identified Risks	Hepatic dysfunction Cardiac arrhythmias Hypertension Hypothyroidism Cardiac dysfunction Posterior reversible encephalopathy syndrome (PRES)
Important Potential Risks	None
Missing Information	None

II.B Summary of Important Risks

The safety information in the proposed Product Information is aligned to the reference medicinal product.

II.C Post-Authorisation Development Plan

II.C.1 Studies Which are Conditions of the Marketing Authorisation

There are no studies which are conditions of the marketing authorisation or specific obligation of Pazopanib Viatriis 200 mg and 400 mg film-coated tablets.

II.C.2 Other Studies in Post-Authorisation Development Plan

There are no studies required for Pazopanib Viatriis 200 mg and 400 mg film-coated tablets.